Date: 2017-07-26
Type of information: Licensing agreement
Compound: ZIKV-VLA1601
Company: Emergent BioSolutions (USA - MD) Valneva (France - Austria)
Therapeutic area: Infectious diseases
Type agreement: licensing - collaboration
Action mechanism: vaccine.
Disease: Zika virus infection
Details:
- • On July 26, 2017, Emergent BioSolutions announced a licensing agreement with Valneva for global exclusive rights to Valneva’s Zika vaccine technology, ZIKV. Emergent and Valneva will co-develop ZIKV-VLA1601, a highly purified inactivated vaccine candidate against the Zika virus, from preclinical development through completion of a Phase 1 safety and immunogenicity clinical trial. The companies plan to initiate the Phase 1 trial in late 2017 or early 2018.
- ZIKV-VLA1601, which has shown to elicit functional antibody responses, is based on Valneva’s established inactivated, whole virus manufacturing platform on which its licensed Japanese Encephalitis vaccine was developed and produced.
- The companies are expected to enter into a technology transfer agreement at a later time to enable transfer of Valneva’s technology to Emergent’s Bayview manufacturing facility in Baltimore, Maryland.
Financial terms:
- Under the terms of the agreement, Emergent will pay Valneva €1 million upfront and will get exclusive rights to use Valneva’s intellectual property and know-how related to Zika product development. Emergent and Valneva will share all costs until the availability of Phase 1 data, which is anticipated within six months from trial initiation. Emergent will have the option to continue the development arrangement with Valneva for a milestone payment of €5 million, upon availability of Phase 1 data. The agreement also provides Valneva potential additional milestone payments of up to €44 million related to product development, approval, commercialization, and product sales, and future royalties on annual net sales.
Latest news:
Is general: Yes
